QANDLI DIABETDA HbA1c KO‘RSATKICHINING KLINIK AHAMIYATI
DOI:
https://doi.org/10.54613/ku.v17i.1409Keywords:
HbA1c, qandli diabet, glikemik nazorat, gemoglobin, monitoring, asoratlar, davolash strategiyasi, mikrovaskulyar, makrovaskulyar, individual maqsadlar.Abstract
Ushbu maqolada qandli diabetda HbA1c ko‘rsatkichining klinik ahamiyati tahlil qilinadi. HbA1c glyukoza bilan gemoglobinning bog‘lanish darajasini aks ettirib, so‘nggi 2–3 oy davomida o‘rtacha glikemik nazoratni baholash imkonini beradi. Maqolada HbA1c ning patofiziologik asoslari, o‘lchash usullari va natijalarni talqin qilish mezonlari yoritiladi. Shuningdek, HbA1c darajalarining mikrovaskulyar (retinopatiya, nefropatiya, neyropatiya) hamda makrovaskulyar asoratlar xavfi bilan bog‘liqligi ko‘rib chiqiladi. Klinik amaliyotda HbA1c davolash strategiyasini tanlash, terapiya samaradorligini monitoring qilish va individual maqsadlarni belgilashda muhim ko‘rsatkich ekani asoslanadi. Maqola diabet turiga, bemor yoshi va komorbid holatlarga mos maqsadli diapazonlarni tanlash zaruratini ta’kidlaydi. Natijalar shuni ko‘rsatadiki, HbA1c ni muntazam nazorat qilish glyukozani barqaror boshqarishga, dori dozasini optimallashtirishga va uzoq muddatli asoratlar xavfini kamaytirishga xizmat qiladi.
Foydalanilgan adabiyotlar:
1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. New England Journal of Medicine. 1993;329(14):977–986.
2. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement 1).
3. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive diabetes treatment on the development and progression of long term complications in the Diabetes Control and Complications Trial. N Engl J Med. 1993;329:977–986.
4. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine. 2010;362(9):800–811.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. The Lancet. 1998;352(9131):837–853.
6. Little RR, Rohlfing CL, Sacks DB. The National Glycohemoglobin Standardization Program: Over 20 years of improving HbA1c measurement. Clinical Chemistry. 2019;65(7):839–848.
7. Saudek CD, Brick JC. The clinical use of hemoglobin A1c. Journal of Diabetes Science and Technology. 2009;3(4):629–634.
8. Beck RW, Bergenstal RM, Laffel LM, et al. Advances in glucose monitoring: CGM and beyond. Diabetes Technology & Therapeutics. 2019;21(S2):S 25–S 36.
9. Cohen RM, Franco RS, Smith EP, Higgins JM. When HbA1c and blood glucose do not match: how much is determined by race, by genetics, by differences in red blood cell lifespan? Journal of Clinical Endocrinology & Metabolism. 2017;102(10):3719–3721.
10. Sacks DB. A1C versus glucose testing: A comparison. Diabetes Care. 2011;34(2):518–523.
Downloads
Published
Iqtiboslik olish
Issue
Section
License
Copyright (c) 2026 QO‘QON UNIVERSITETI XABARNOMASI
This work is licensed under a Creative Commons Attribution 4.0 International License.